GBT - Global Blood Therapeutics, Inc.
| Previous Close | 41.40 |
| Open | 41.10 |
| Bid | 39.60 x 2900 |
| Ask | 40.90 x 800 |
| Day's Range | 39.70 - 41.75 |
| 52 Week Range | 27.55 - 68.05 |
| Volume | 1,042,641 |
| Avg. Volume | 1,230,811 |
| Market Cap | 2.069B |
| Beta | 4.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.25 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.21 |
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: ...
- Kiplinger•7 days ago
Oppenheimer’s 7 Top Stock Picks for September
Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has released a bullish report highlighting its latest Top Stock Picks for September 2018. "These are the most timely stocks in the opinion of our research analysts" stated the firm. "Each analyst was asked to contribute the one idea they considered to outperform over the next 12 months, based on their view of the company's fundamentals in the context of current market conditions." The report lists 30 top stocks. But here I focus on the seven stocks that truly stand out from the crowd. I used TipRanks' market data to cherry-pick the report's best stocks. These are the the stocks which boast a "strong buy" consensus rating from the Street. This is based on all the ratings each stock has received over the last three months. That way we have the added reassurance of knowing that these stocks score big across the board.Let's take a closer look at these hot shots now: SEE ALSO FROM KIPLINGER: 12 Top Stock Picks to Shield Your Portfolio
- Zacks•7 days ago
Are Options Traders Betting on a Big Move in Global Blood (GBT) Stock?
Investors need to pay close attention to Global Blood (GBT) stock based on the movements in the options market lately.
- Business Wire•10 days ago
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (“Global Blood” or “the Company”) (NASDAQ: GBT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Stat published an article about Global Blood, claiming that there are “important risks that investors might be glossing over” about the likelihood of Global Blood’s new drug for sickle cell disease, voxelotor, being approved by the FDA.
- ACCESSWIRE•10 days ago
Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Global Blood Therapeutics
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Wall Street closed up on Thursday as tech shares rallied and trade tensions eased on the hopes of a fresh round of trade talks, that could potentially take ...
- Business Wire•11 days ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Global Blood Therapeutics, Inc. – GBT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc. resulting from allegations that Global Blood may have issued materially misleading business information to the investing public.
- GlobeNewswire•11 days ago
Bragar Eagel & Squire, P.C. is Investigating Global Blood Therapeutics, Inc. (GBT) on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Sept. 13, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims against Global Blood Therapeutics, Inc.. Our investigation concerns whether Global Blood has violated the federal ...
- PR Newswire•11 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT
NEW YORK , Sept. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: ...
- PR Newswire•11 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)
NEW YORK , Sept. 13, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global ...
- InvestorPlace•12 days ago
Bluebird Bio Stock May Have Upside of at Least 60 Percent
Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?
- GlobeNewswire•17 days ago
GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018-- Global Blood Therapeutics, Inc. today announced that it will present at the 2018 Morgan Stanley Global Healthcare Conference in New York City on Friday, September ...
- GlobeNewswire•18 days ago
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018-- Global Blood Therapeutics, Inc. today announced that, on September 4, 2018, the compensation committee of the Company’ s board of directors granted five new ...
- GlobeNewswire•18 days ago
GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting SCD Community During National SCD Awareness Month. Livestream of Conference Will Be Available through Collaboration ...
- TheStreet.com•19 days ago
3 Biotech Stocks Ready to Burn Up
It's clear that healthcare stocks are dynamite right now on Wall Street. The biotech giant has unleashed a slew of blockbuster drugs - neuropathic pain and fibromyalgia drug Lyrica, antibiotic Zithromax, E.D. drug Viagra, to name a few. Consider Pfizer's heart drug Tafamidis, another potential blockbuster drug that could shake up the market.
- InvestorPlace•27 days ago
Oppenheimer’s 7 Top Stock Picks for September
Investment firm Oppenheimer has just released a bullish report highlighting its latest Top Stock Picks for August-September 2018. “These are the most timely stocks in the opinion of our research analysts” stated the firm.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Immunomedics and Global Blood Therapeutics
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...
- GlobeNewswire•last month
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
Global Blood Therapeutics, Inc. (GBT) (GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of inclacumab, a novel fully human monoclonal antibody against P-selectin. Under the terms of the agreement, GBT will be responsible for all development, manufacturing, and commercialization of inclacumab worldwide.
- GlobeNewswire•last month
GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs. At GBT, Ms. Wagner will create and lead the Company’s government affairs and public policy function, initially focused on concerns related to the sickle cell disease (SCD) community.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Cronos Group and Global Blood Therapeutics
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / U.S. markets retreated on Wednesday as ongoing trade concerns and the currency crisis in Turkey continued to take center stage. The Dow Jones Industrial Average ...
- GlobeNewswire•2 months ago
GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- Global Blood Therapeutics, Inc. today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 14 ...
- GlobeNewswire•2 months ago
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018-- Global Blood Therapeutics, Inc. today announced that, on August 1, 2018, the compensation committee of the Company’ s board of directors granted two new employees ...
- Associated Press•2 months ago
Global Blood: 2Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 78 cents. The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by ...
- GlobeNewswire•2 months ago
GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018-- Global Blood Therapeutics, Inc. today reported business progress and financial results for the second quarter ended June 30, 2018.. "We continue to advance ...
- American City Business Journals•2 months ago
A guide to biotech’s building boom in South City
The pieces have begun to come together for South San Francisco’s biotech space puzzle. Here’s the latest info on who’s doing what where.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Global Blood Therapeutics
NEW YORK, NY / ACCESSWIRE / July 26, 2018 / U.S. equities closed up on Wednesday, as trade tension eased following the President Trump's statement that the U.S. and the EU will "work together toward ...
